Pharma-Bio Serv (PBSV) Cash from Financing Activities (2010 - 2026)
Pharma-Bio Serv's (PBSV) quarterly Cash from Financing Activities came in at -$1.7 million in Q2 2026, up 1.08% on a YoY basis from -$1.7 million in Q2 2025, and down 102121.06% quarter-over-quarter from -$1681.0 in Q1 2026.
Powered by 
Analysis
Pharma-Bio Serv (PBSV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Pharma-Bio Serv (PBSV) has reported Cash from Financing Activities for 17 consecutive years, with -$1.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities rose 1.08% year-over-year to -$1.7 million; the trailing twelve-month figure through Apr 2026 stood at -$1.7 million (changed 0.27% YoY), and the FY2025 full-year result was -$1.8 million, down 1.03% from the prior year.
- Cash from Financing Activities retreated to -$1.7 million in Q2 2026 per PBSV's latest filing, from -$1681.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$792.0 in Q4 2023 and bottomed at -$1.8 million in Q1 2022.
- Historically, Cash from Financing Activities has averaged -$699441.8 across 5 years, with a median of -$9202.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 62248.3% in 2022, then surged 66.71% in 2023.
- Over 5 years, Cash from Financing Activities stood at -$2379.0 in 2022, then jumped by 66.71% to -$792.0 in 2023, then tumbled by 120.58% to -$1747.0 in 2024, then plunged by 426.73% to -$9202.0 in 2025, then slumped by 18573.51% to -$1.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.7 million, -$1681.0, and -$9202.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 124.62 Bn | 115.58 Bn | 6.13 Bn | -1.77 Bn |
| 2 | UL Solutions | 14.92 Bn | 14.51 Bn | 417.00 Mn | -114.00 Mn |
| 3 | Gartner | 11.76 Bn | 10.28 Bn | 1.19 Bn | -545.98 Mn |
| 4 | Tetra Tech | 9.19 Bn | 8.96 Bn | 243.21 Mn | -200.52 Mn |
| 5 | Booz Allen Hamilton Holding | 8.76 Bn | 8.22 Bn | 1.46 Bn | -141.00 Mn |
| 6 | Genpact | 6.27 Bn | 5.75 Bn | 490.34 Mn | -440.95 Mn |
| 7 | Korn Ferry | 4.28 Bn | 3.15 Bn | 685.99 Mn | -107.45 Mn |
| 8 | Fti Consulting | 4.20 Bn | 4.04 Bn | 316.27 Mn | -133.99 Mn |
| 9 | Grand Canyon Education | 4.01 Bn | 3.73 Bn | 204.08 Mn | -75.28 Mn |
| 10 | Pharma-Bio Serv | 12.37 Mn | 3.89 Mn | 902,041.00 | -1.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -1.72 Mn |
| Jan 31, 2026 | -1,681.00 |
| Oct 31, 2025 | -9,202.00 |
| Jul 31, 2025 | -5,004.00 |
| Apr 30, 2025 | -1.74 Mn |
| Jul 31, 2024 | -1,747.00 |
| Apr 30, 2024 | -1.72 Mn |
| Jan 31, 2024 | -7,193.00 |
| Oct 31, 2023 | -792.00 |
| Jul 31, 2023 | -5,083.00 |
| Apr 30, 2023 | -1.75 Mn |
| Oct 31, 2022 | -2,379.00 |
| Jul 31, 2022 | -9,327.00 |
| Apr 30, 2022 | -1.74 Mn |
| Jan 31, 2022 | -1.78 Mn |
| Oct 31, 2021 | 41,113.00 |
| Apr 30, 2021 | -1.79 Mn |
| Jan 31, 2021 | -2,851.00 |
| Oct 31, 2020 | 8,217.00 |
| Jul 31, 2020 | -2,776.00 |